|
Morepen Laboratories Limited announced its financial results for the quarter ended June 30, 2026, reporting its highest-ever quarterly revenue and highest-ever quarterly earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate.
The company's revenue stood at Rs. 575.31 crore, up 34% YoY, while PAT was at Rs. 56.35 crore, up 394% YoY.
The first quarter also marked a major strategic milestone as Morepen’s previously announced Rs. 825 crore CDMO mandate entered full scale commercialization phase, with Rs. 58 crore worth of commercial CDMO dispatches already completed during the quarter. This marks the commercial validation of the company’s Morepen 2.0 strategy, focused on moving from traditional commodity APIs toward innovation-led manufacturing, long-duration CDMO partnerships, recurring customer programs and a scalable operating platform.
Commenting on the performance, Sushil Suri, chairman & managing director, Morepen Laboratories Limited, said: “Q1 FY27 marks an important validation of Morepen’s transformation journey. The company has delivered its highest-ever quarterly revenue, strong profitability improvement and meaningful operating leverage. More importantly, our Rs. 825 crore CDMO mandate has now entered full scale commercial execution, reinforcing our shift from a transaction-led API business to a more focused, manufacturing-led platform built around long-duration global partnerships.”
“With API profitability recovering, exports growing strongly and medical devices continuing to scale as a second growth engine, Morepen is entering the next phase with greater confidence. Our focus remains on disciplined execution, capacity expansion, customer diversification and building deeper scientific and compliance capabilities to create a stronger, more predictable and globally relevant Morepen.”
Morepen’s API business recorded 31% growth, supported by a healthy recovery in the base business, improved product mix, customer prioritisation and better operating discipline. API exports grew 42%, reflecting stronger traction in global markets. The Company believes that a stronger API base will support the transition toward a higher-quality CDMO platform.
The company’s regulatory and quality track record continues to support its global manufacturing ambitions. Morepen has completed four consecutive US FDA inspections with Nil Form 483 observations, strengthening its credibility with global pharmaceutical customers and supporting long-term CDMO partnerships. To support larger global CDMO opportunities, Morepen is expanding its manufacturing capacity in phases. The company’s capacity roadmap envisages expansion upto 1,200 KL by FY30.
|